Indications and efficacy of the human papillomavirus vaccine

Current Treatment Options in Oncology

Volumn 8, Issue 6, 2007, Pages 393-401

  Hakim, Amy A ^a   Lin, Paul S ^a   Wilczynski, Sharon ^a   Nguyen, Kimhuynh ^a   Lynes, Billie ^a   Wakabayashi, Mark T ^a  

^a Department of Gynecologic Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ANUS CANCER; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ERYTHEMA; GASTROENTERITIS; HEADACHE; HEALTH INSURANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; IMMUNIZATION; INJECTION SITE PAIN; LACTATION; MOTOR DYSFUNCTION; PAPANICOLAOU TEST; PENIS CANCER; PREGNANCY; REVIEW; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUALLY TRANSMITTED DISEASE; SWELLING; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; UTERINE CERVIX DYSPLASIA; VAGINA BLEEDING; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS; ALPHAPAPILLOMAVIRUS; DRUG EFFECT; FEMALE; MALE; UTERINE CERVIX TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 40749090093     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0050-0     Document Type: Review

References (32)

1. Centers for Disease Control and Prevention: Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007, 56(Early Release): 1-24
2. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human Papillomavirus. Obstet Gynecol 2005, 105: 905-918
3. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55: 74-108
4. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578
5. World health report 2004: Changing history. Statistical annex. World health organization. 2004 [updated 2004; cited]; http://www/who.int/whr/ 2004/en/index/htm
6. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus in cervical cancer. J Clin Pathol 2002;55:244-265
7. Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 31: 14-19
8. Syrjanen S. Human Papillomaviruses in head and neck carcinomas. N Engl J Med 2007;356:1993-1995
9. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
10. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
11. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101-106.
12. Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K: Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001, 91: 947-952
13. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343-347.
14. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human Papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.
15. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S. Determinants of clearance of human Papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486-494.
16. Tjalma WA, van Damme P. Who should be vaccinated against human papillomavirus? Int J Gynecol Cancer 2006;16:1498-1499.
17. Human Papillomavirus (HPV): http://www.acog.org/departments/govtrel/ FactSheetHPV20070223.pdf
18. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics,2004. CA Cancer J Clin 2004;54:8-29.
19. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human Papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women. Br J Cancer 2001;84:616-623.
20. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, Hildesheim A, Lorincz AT, Greenberg MD, Morales J, Schiffman M. Utility of liquid-based cytology for cervical carcinoma screening: Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87:48-55.
21. ACOG Committee Opinion No. 344: Human Papillomavirus vaccination. Obstet Gynecol 2006, 108: 699-705
22. ACOG Committee Opinion #300: Cervical cancer screening in adolescents. Obstet Gynecol 2004, 104: 885-889
23. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Jr, Reisinger KS. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human Papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-2145.
24. Frazer IH, Cox JT, Mayeaux EJ, Jr, Franco EL, Moscicki AB, Palefsky JM, Ferris DG, Ferenczy AS, Villa LL: Advances in prevention of cervical cancer and other human Papillomavirus-related diseases. Pediatr Infect Dis J 2006, 25: S65-S81, quiz S82
25. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human Papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 2004;364:1757-1765.
26. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 2006;367:1247-1255.
27. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356: 1915-1927.
28. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943.
29. Food and Drug Administration. Product approval information-licensing action [package insert]. Gardasil (quadrivalent human papillomavirus types 6, 11, 16, and 18). Merck & Co., Whitehouse Station, NJ. Available at http://www.fda.gov/cber/label/HPVmer060806LB.pdf
30. Centers for Disease Control and Prevention: General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002, 51 (No. RR-2): 1-35
31. HPV vaccine - ACOG recommendations [cited]; Available from: http://www.acog.org/departments/dept_notice.cfm?recno=7&bulletin=3945
32. Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against human papillomavirus. Hum Vaccin 2006;2:243-248.